These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33830971)

  • 21. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
    Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
    Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
    Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs in gastrointestinal stromal tumors.
    Martin-Broto J; Moura DS
    Curr Opin Oncol; 2020 Jul; 32(4):314-320. PubMed ID: 32541319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
    Symcox M; Somaiah N
    Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib in advanced GIST: if it's working, don't stop a good thing.
    Denu RA; Somaiah N
    Lancet Oncol; 2024 Sep; 25(9):1105-1107. PubMed ID: 39127065
    [No Abstract]   [Full Text] [Related]  

  • 26. [Novel molecular-targeted agents for GIST(Regorafenib etc.)].
    Naito Y; Doi T
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):15-8. PubMed ID: 23306914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
    Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.
    Fung S; Shirley M
    Drugs; 2022 Oct; 82(15):1541-1548. PubMed ID: 36282417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.
    Vadakara J; von Mehren M
    Hematol Oncol Clin North Am; 2013 Oct; 27(5):905-20. PubMed ID: 24093167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition.
    Sun H; Cui Z; Li C; Gao Z; Xu J; Bian Y; Gu T; Zhang J; Li T; Zhou Q; Yang D; He Z; Li B; Li F; Xu Z; Xu H
    Adv Sci (Weinh); 2024 Sep; 11(34):e2401171. PubMed ID: 38973363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2015; 11(12):1829-43. PubMed ID: 26075449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
    Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
    Yoo C; Ryu MH; Nam BH; Ryoo BY; Demetri GD; Kang YK
    Eur J Cancer; 2016 Jan; 52():201-8. PubMed ID: 26699729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
    Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
    JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Efficacy and Safety of Different Regimens of Advanced Gastrointestinal Stromal Tumors After Failure Prior Tyrosine Kinase Inhibitors: A Network Meta-Analysis.
    Zhang X; Liang Y; Li Y; Yin J
    Adv Ther; 2021 Jan; 38(1):399-412. PubMed ID: 33131035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.